ValuEngine Upgrades Fibrocell Science (NASDAQ:FCSC) to Hold

Fibrocell Science (NASDAQ:FCSC) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a report issued on Thursday, ValuEngine reports.

Separately, Zacks Investment Research raised Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th.

Shares of NASDAQ:FCSC traded down $0.03 during trading on Thursday, hitting $1.82. The stock had a trading volume of 27,531 shares, compared to its average volume of 36,414. Fibrocell Science has a 12 month low of $1.45 and a 12 month high of $3.28. The company has a market cap of $18.05 million, a P/E ratio of -1.26 and a beta of 1.60. The company has a fifty day moving average of $1.89. The company has a debt-to-equity ratio of 0.85, a current ratio of 3.59 and a quick ratio of 3.59.

Fibrocell Science (NASDAQ:FCSC) last announced its earnings results on Wednesday, May 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.07). As a group, equities analysts expect that Fibrocell Science will post -1.31 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Fibrocell Science stock. Virtu Financial LLC lifted its stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 90.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,864 shares of the company’s stock after acquiring an additional 18,958 shares during the quarter. Virtu Financial LLC owned approximately 0.41% of Fibrocell Science worth $77,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 28.04% of the company’s stock.

About Fibrocell Science

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Further Reading: What is the balance sheet?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.